2 weeks Ago By [email protected] (MENAFN)
PERTH, Australia, March 16, 2025 /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF ), a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments for central nervous system and immune-related disorders through neuro-immune modulation and advanced nano-medicine technology, is pleased to announce positive Phase IIb clinical trial results for CimetrA®, a novel anti-inflammatory treatment. The study confirmed CimetrA®'s strong safety profile and demonstrated faster recovery times in COVID-19 patients.
Key Findings: CEO Roby Zomer stated: "These promising results highlight CimetrA®'s potential as a breakthrough treatment for inflammatory diseases beyond COVID-19. We are excited about its future clinical development." With these findings, Argent BioPharma continues to advance innovative therapies.
One such therapy, CannEpil ®, is an oral mucosal solution with a high-CBD, low-THC formulation. It is designed to reduce seizure frequency and severity while minimizing psychoactive effects. After years of clinical development, CannEpil ® is making waves in the UK as part of a movement to transform severe epilepsy treatment.
This further reinforces Argent BioPharma's commitment to addressing global health challenges. For further information, please contact: Argent BioPharma Roby Zomer CEO & Managing Director +61 8 6555 2950 [email protected] Argent BioPharma Rowan Harland Company Secretary +61 8 6555 2950 [email protected] SOURCE Argent BioPharma Ltd. MENAFN16032025003732001241ID1109320485 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind.
We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above..
